BioLargo, Inc. 

(Public, OTC:BLGO)   Watch this stock   
Find more results for BLGO
Nov 16, 2009
Q3 2009 NuWay Medical, Earnings Release
  

Key stats and ratios

Q2 (Jun '09) 2008
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -78.58% -66.55%
Return on average equity -124.10% -87.00%
Employees 3 -

Address

2603 Main Street Suite 1155
Irvine, CA 92614
United States - Map
+1-949-2358062 (Phone)
+1-949-6259819 (Fax)

Website links

BioLargo, Inc. discussions

  View all discussions »

Description

BioLargo, Inc. is engaged in pre-licensing and product evaluation with strategic partners to leverage a suite of patented and patent-pending intellectual property, the BioLargo technology. The BioLargo technology, the centerpiece of which is CupriDyne, works by combining minerals and salts with water from any source to generate and deliver molecular iodine on demand, in controlled dosages, in order to balance efficacy of disinfectant performance with concerns about toxicity. In addition to its BioLargo technology, the Company acquired the rights to market an iodine based water disinfection system (the Isan system) from Ioteq IP Pty. Ltd., an Australian company, and its United States affiliate Ioteq Inc. during the year ended December 31, 2008. The Isan system is an automated water disinfection system that substantially reduces the incidence of fungal growth, spoilage, organisms and pathogens in water and on food.

Officers and directors

Dennis P. Calvert
Chairman of the Board, President, Chief Executive Officer
Age: 46
Charles K. Dargan II
Chief Financial Officer
Age: 53
Joseph Provenzano
Executive Vice President - Operations, Corporate Secretary, Director
Age: 40
Kenneth R. Code
Chief Technology Officer, Director
Age: 62
Gary A. Cox
Director
Age: 47
Dennis E. Marshall
Director
Age: 66